Efficacy of three methods in the treatment of androgenic alopecia

Comparison of three methods of platelet-rich plasma, platelet rich plasma in combination with finasteride, and finasteride alone in the treatment of androgenic alopecia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138902081159N3

Enrollment

Registered

2013-07-12

Start date

2012-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic alopecia. male-pattern baldness

Interventions

Intervention 1: Finastride (Soha drug company) 1 mg/day for 12 months. Intervention 2: Finastride (Soha drug company) 1mg/day for 12 months + PRP injection into bald scalp areas, 2 times with 3 month

Treatment - Drugs

Finastride (Soha drug company) 1 mg/day for 12 months

Finastride (Soha drug company) 1mg/day for 12 months + PRP injection into bald scalp areas, 2 times with 3 month intervals, every time 10 cc (in every cm of bald scalp 0.1 cc injection with use of bi

PRP injection into bald scalp areas, 2 times with 3 month intervals, every time 10 cc (in every cm of bald scalp 0.1 cc injection with use of biogel kit)

Eligibility

Sex/Gender

Male

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Men with androgenic alopecia referred to Skin and Stem Cell Research Center Clinics who are not willing to do hair transplantation Exclusion Criteria: 1- History of allergy or sensitivity to finastride 2- Abnormal findings in physical examination or hormonal tests 3- History of taking finastride or other 5- alfa reductase inhibitors within last 12 months 4- History of taking antiandrogenic drugs or minoxidil application during past 6 months 5- Lack of cooperation of patients or unwilling for participating in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hair diameter. Timepoint: Before intervention and every three months after intervention. Method of measurement: trichoscan.;Hair Density. Timepoint: Before intervention and every three months after intervention. Method of measurement: trichoscan.;Patient satisfaction. Timepoint: 3,6,9 and 12 months after treatment. Method of measurement: VAS(0-10).;Physician rating scale. Timepoint: 3,6,9 and 12 months after treatment. Method of measurement: 0-7.	—

Measure

Time frame

Hair diameter. Timepoint: Before intervention and every three months after intervention. Method of measurement: trichoscan.;Hair Density. Timepoint: Before intervention and every three months after intervention. Method of measurement: trichoscan.;Patient satisfaction. Timepoint: 3,6,9 and 12 months after treatment. Method of measurement: VAS(0-10).;Physician rating scale. Timepoint: 3,6,9 and 12 months after treatment. Method of measurement: 0-7.

—

Secondary

Measure	Time frame
Side effects of treatment. Timepoint: 3, 6, 9 and 12 months after treatment. Method of measurement: check list.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Zolfaghari

Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Ir

ms_a_zoolfaghari@yahoo.com+98 31 1337 3736

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026